Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Precision Treatment of Rare Tumours Guided by PDO and NGS
NCT06692491Phase 2Not yet recruiting
- Sponsor
- Peking University Shenzhen Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2027
01
Overview
Phase 2, open-label trial, sponsored by Peking University Shenzhen Hospital. Primary endpoint: Objective Response Rate at 8 weeks. Planned start Jan 2025; status: not yet recruiting.
Beyond the preview
Go deeper on NCT06692491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06692491.